Prosztatarák: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• PSMA 273
• AR 16
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• PI3K 2
• STAT3 0
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• AMPK 0
• CDK4/6 4
• HER2 6
• MAPK 0
• NRF2 0
• FAK 0
• YAP 0
• PPAR 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• ATM 1
• HDAC 0
• IL-15 4
• METTL3 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting stress signaling pathways to enhance prostate cancer immunotherapy (IMMSTRESS)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 202 125 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Circulating Tumor Cell-informed RADioresponse Assessment from heme-axis signatuRes (CTC-RADAR)

  Koc University· Istanbul, Törökország· EU contribution 398 612 EUR· until 2029. dec.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Görögország· EU contribution 796 590 EUR· until 2030. dec.· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploitation of bioorthogonal click-to-release chemistry for precision cancer therapy (click-to-cure)

  Kobenhavns Universitet· Kobenhavn, Dánia· EU contribution 247 553 EUR· until 2028. dec.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Proteoform-Resolved Lateral Flow Immunoassay with Antibody Mimics and Engineered Release for Precise Prostate Cancer Diagnosis (PRIME)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, Egyesült Királyság· EU contribution 260 348 EUR· until 2028. szept.

• European Commission (Horizon Europe) · HORIZON-EIC

  PROstate cancer Multimodal Explainable Transferable Holistic Expert for Universal Stratification (PROMETHEUS)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 3 975 619 EUR· until 2030. szept.· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Proximity-Driven Polyvalent RIPTAC Innovation for Molecular Eradication of Prostate Cancer (PRIME-PCa)

  Universidad de Santiago de Compostela· Santiago De Compostela, Spanyolország· EU contribution 194 075 EUR· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  Deconvolution of tumor evolution and ecosystem through EV-based liquid biopsy (EVOLVE)

  Fundacion de la Comunidad Valenciana Centro de Investigacion Principe Felipe· Valencia, Spanyolország· EU contribution 1 987 583 EUR· until 2031. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Tunable Radiolabelled Agents based on Molecular Cages for Theranostics (TRACE)

  Universitat Zurich· Zurich, Svájc· EU contribution 292 119 EUR· until 2028. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Risk-Stratified and Personalized Cancer Screening with Bidirectional Multistate Markov Models (MarkovForScreening)

  Tampereen Korkeakoulusaatio Sr· Tampere, Finnország· EU contribution 242 117 EUR· until 2028. jún.· 2 countries

10 of 32 running projects, newest first. Listed amounts together: 116,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 42
• Organoids 15
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 14
• Gene Expression Profiling 153
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 32
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 125
• Magnetic Resonance Imaging 464
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 276
• Genome-Wide Association Study 61

• Patient-derived models of prostate cancer: Capturing tumour complexity from initiation to metastasis.

  Cancer Lett, 2026. aug.

• Establishment and Characterization of Patient-Derived Xenograft Organoids for Personalized Treatment of Castration-Resistant Prostate Cancer.

  Prostate, 2026. máj.

• Protocol for generating and characterizing Matrigel-free prostate cancer patient-derived organoids.

  STAR Protoc, 2026. ápr.

• Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review.

  Eur Urol Oncol, 2026. ápr.

• Unmasking prostate cancer risk factors leveraging organoid technology.

  Gene, 2026. ápr.

• Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss.

  Cell Rep Methods, 2026. márc.

• [Construction of a membrane-anchored bifunctional growth factor mimetic and its application in organoid culture].

  Sheng Wu Gong Cheng Xue Bao, 2026. márc.

• Generation of a Mouse Prostate Organoid-Based Model for Studying Host-Pathogen Interactions.

  J Vis Exp, 2026. febr.

• FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity.

  Cell Rep, 2026. jan.

• Adiponectin receptor agonist, AdipoRon, reduces the growth of prostate cancer cells and patient-derived organoids.

  Life Sci, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.